Page 134 - Cardiac Nursing

10.
e 1
g
10
q
xd
10
0 A
p
7-1
0 A
e 1
q
009
Pa
ara
ara
Pa
M
M
M
0/0
6/2
q
0/0
1
1
3
7-1
10.
ara
009
6/2
3
3
A
LWB
LWBK340-c04_
LWB K34 0-c 04_ p pp097-110.qxd 30/06/2009 10:40 AM Page 110 Aptara
04_
0-c
K34
0:4
p
09
A
09
p
xd
g
g
0:4
t
p
t
110 PA R T I I / Physiologic and Pathologic Responses
158. Brown, G., Albers, J. J., Fisher, L. D., et al. (1990). Regression of coro- 176. Reaven, G. M., & Chen, Y. D. (1988). Role of insulin in regulation of
nary artery disease as a result of intensive lipid-lowering therapy in men lipoprotein metabolism in diabetes. Diabetes Metabolism Review, 4(7),
with high levels of apolipoprotein B. New England Journal of Medicine, 639–652.
323(19), 1289–1298. 177. Bensen, J. T., Liese, A. D., Rushing, J. T., et al. (1999). Accuracy of
159. Downs, J. R., Clearfield, M., Weis, S., et al. (1998). Primary prevention proband reported family history: The NHLBI Family Heart Study
7
of acute coronary events with lovastatin in men and women with aver- (FHS). Genetic Epidemiology, 17(2), 141–150.
7
age cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas 178. Kahn, L. B., Marshall, J. A., Baxter, J., et al. (1990). Accuracy of re-
Coronary Atherosclerosis Prevention Study. JAMA, 279(20), ported family history of diabetes mellitus. Results from San Luis Valley
1615–1622. Diabetes Study. Diabetes Care, 13(7), 796–798.
160. Jukema, J. W., Bruschke, A. V., van Boven, A. J., et al. (1995). Effects of 179. Kee, F., Tiret, L., Robo, J. Y., et al. (1993). Reliability of reported
lipid lowering by pravastatin on progression and regression of coronary family history of myocardial infarction. BMJ, 307(6918), 1528–
artery disease in symptomatic men with normal to moderately elevated 1530.
serum cholesterol levels. The Regression Growth Evaluation Statin Study 180. Fraser, F. C. (1974). Genetic counseling. American Journal of Human Ge-
(REGRESS). Circulation, 91(10), 2528–2540. netics, 26(5), 636–661.
6
6
161. Kreisberg, R. A. (1996). Cholesterol-lowering and coronary atheroscle- 181. Statement on use of DNA testing for presymptomatic identification of
rosis: Good news and bad news. American Journal of Medicine, 101(5), cancer risk. National Advisory Council for Human Genome Research
455–458. (1994). JAMA, 271(10), 785.
162. Genest, J. J., Jr., Martin-Munley, S. S., McNamara, J. R., et al. (1992). 182. The American Society of Human Genetics. (1996). Statement on in-
Familial lipoprotein disorders in patients with premature coronary artery formed consent for genetic research. ASHG report. American Journal of
disease. Circulation, 85(6), 2025–2033. Human Genetics, 59(2), 471–474.
163. Szapary, P. O., & Rader, D. J. (2004). The triglyceride-high-density 183. Geller, G., Botkin, J. R., Green, M. J., et al. (1997). Genetic testing for
lipoprotein axis: An important target of therapy? American Heart Jour- susceptibility to adult-onset cancer. The process and content of informed
7
nal, 148(2), 211–221. consent. JAMA, 277(18), 1467–1474.
7
164. Brattstrom, L., Israelsson, B., Norrving, B., et al. (1990). Impaired ho- 184. McKinnon, W. C., Baty, B. J., Bennett, R. L., et al. (1997). Predisposi-
mocysteine metabolism in early-onset cerebral and peripheral occlusive tion genetic testing for late-onset disorders in adults. A position paper of
arterial disease. Effects of pyridoxine and folic acid treatment. Athero- the National Society of Genetic Counselors. JAMA, 278(15),
sclerosis, 81(1), 51–60. 1217–1220.
165. Brattstrom, L. E., Israelsson, B., Jeppsson, J. O., et al. (1988). Folic 185. Tamragouri, R. N., Martin, R. W., Cleavenger, R. L., et al. (1986). Car-
acid—An innocuous means to reduce plasma homocysteine. Scandina- diovascular risk factors and health knowledge among freshman college
vian Journal of Clinical Laboratory Investigations, 48(3), 215–221. students with a family history of cardiovascular disease. Journal of the
166. Ubbink, J. B. (1997). The role of vitamins in the pathogenesis and treat- American College of Health, 34(6), 267–270.
ment of hyperhomocyst(e)inaemia. Journal of Inherited Metabolic Disor- 186. Croyle, R. T., Smith, K. R., Botkin, J. R., et al. (1997). Psychological re-
ders, 20(2), 316–325. sponses to BRCA1 mutation testing: Preliminary findings. Health Psy-
167. Rumberger, J. A., Simons, D. B., Fitzpatrick, L. A., et al. (1995). Coro- chology, 16(1), 63–72.
6
6
nary artery calcium area by electron-beam computed tomography and 187. Hudson, K. L., Rothenberg, K. H., Andrews, L. B., et al. (1995). Ge-
coronary atherosclerotic plaque area. A histopathologic correlative study. netic discrimination and health insurance: An urgent need for reform.
Circulation, 92(8), 2157–2162. Science, 270(5235), 391–393.
168. Schmermund, A., Baumgart, D., Adamzik, M., et al. (1998). Compari- 188. Lerman, C., Narod, S., Schulman, K., et al. (1996). BRCA1 testing in
son of electron-beam computed tomography and intracoronary ultra- families with hereditary breast-ovarian cancer. A prospective study of pa-
sound in detecting calcified and noncalcified plaques in patients with tient decision making and outcomes. JAMA, 275(24), 1885–1892.
acute coronary syndromes and no or minimal to moderate angiographic 189. Rothenberg, K., Fuller, B., Rothstein, M., et al. (1997). Genetic infor-
coronary artery disease. American Journal of Cardiology, 81(2), 141–146. mation and the workplace: Legislative approaches and policy changes.
169. Arad, Y., Spadaro, L. A., Goodman, K., et al. (1996). Predictive value of Science, 275(5307), 1755–1757.
electron beam computed tomography of the coronary arteries. 19-month 190. Billings, P. R., Kohn, M. A., de Cuevas, M., et al. (1992). Discrimina-
follow-up of 1173 asymptomatic subjects. Circulation, 93(11), 1951–1953. tion as a consequence of genetic testing. American Journal of Human Ge-
170. Raggi, P., Callister, T. Q., Cooil, B., et al. (2000). Identification of pa- netics, 50(3), 476–482.
tients at increased risk of first unheralded acute myocardial infarction by 191. Geller, L. N., Alper, J. S., Billings, P. R., et al. (1996). Individual, fam-
electron-beam computed tomography. Circulation, 101(8), 850–855. ily, and societal dimensions of genetic discrimination: A case study
171. Secci, A., Wong, N., Tang, W., et al. (1997). Electron beam computed analysis. Science and Engineering Ethics, 2(1), 71–88.
tomographic coronary calcium as a predictor of coronary events: Com- 192. Reilly, P. R. (1998). Genetic risk assessment and insurance. Genetic Test-
parison of two protocols. Circulation, 96(4), 1122–1129. ing, 2(1), 1–2.
6
6
172. Detrano, R., Hsiai, T., Wang, S., et al. (1996). Prognostic value of coro-
nary calcification and angiographic stenoses in patients undergoing coro-
7
nary angiography. Journal of the American College of Cardiology, 27(2), W E B R E SOURC ES
7
285–290.
173. Iyengar, S. K., & Elston, R. C. (2007). The genetic basis of complex International Societies of Nurses in Genetics:
traits: Rare variants or “common gene, common disease”? Methods in www.globalreferrals.com/isong.html
6
6
Molecular Biology, 376, 71–84. National Center for Biotechnology Information:
174. Kathiresan, S., Musunuru, K., & Orho-Melander, M. (2008). Defining www.ncbi.nlm.nih.gov
the spectrum of alleles that contribute to blood lipid concentrations in Department of Energy/Human Genome Project Information:
humans. Current Opinion in Lipidology, 19(2), 122–127. www.ornl.gov/TechResources/Human_Genome/publicat/primer/index.html
175. Scheuner, M. T., Wang, S. J., Raffel, L. J., et al. (1997). Family history: The International Atherosclerosis Society:
A comprehensive genetic risk assessment method for the chronic condi- www.athero.org/
tions of adulthood. American Journal of Medical Genetics, 71(3), The American Heart Association:
315–324. www.americanheart.org